The fact that what IMO should have been the CEO's most important statement of the year for ADR in its " transformative year" is not classed as price sensitive says it all!
If the CEO has nothing to say about the companies future prospects " in its multiple channels" thats price sensitive after £13.5m raise; the registration of 3 of its "impactful", "next generation" products of its latest tech; the success of its new partnerships and no detail of its " first remote patient monitoring revenue" or patient numbers, whats the point of the CEO and more broadly, whats the point ?
The fact that what IMO should have been the CEO's most important...
Add to My Watchlist
What is My Watchlist?
